{"success":true,"data":{"pressRelease":{"id":"4840","rtpr_id":"nACSC7x6Ma","ticker":"XBIO","exchange":"NASDAQ","all_tickers":["XBIO"],"title":"Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting","author":"ACCESSWIRE","published_at":"2026-04-22T13:00:02.957Z","article_body":"FRAMINGHAM, MA / ACCESS Newswire (https://www.accessnewswire.com/) / April 22,\n2026 / Xenetic Biosciences, Inc. (https://pr.report/kvr3) (NASDAQ:XBIO)\n(\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing\ninnovative immuno-oncology technologies addressing difficult to treat cancers,\ntoday announced that its abstract has been accepted for presentation at the\n2026 American Society of Clinical Oncology (ASCO) Annual Meeting\n(https://pr.report/kvr4), taking place May 29 - June 2, 2026, in Chicago, IL.\n(https://app.accessnewswire.com/imagelibrary/270296a6-00d1-405c-ad8e-010cf3e62669/1159779/xenetic-newlogo-031226.jpg)\nThe accepted abstract, titled \"Targeting cfDNA and NETs with DNase I to\naugment CAR T cell function and antitumor efficacy,\" highlights preclinical\nresearch supporting Xenetic's DNase-based therapeutic approach designed to\nenhance CAR T-cell activity and improve antitumor responses.\n\nPresentation Details:\n*\nSession Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster\nSession)\n*\nAbstract Title: Targeting cfDNA and NETs with DNase I to augment CAR T cell\nfunction and antitumor efficacy\n*\nPoster Board: 410\n*\nPresentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT\n*\nPresenter: Alexey V. Stepanov, PhD\n\nThe poster will be available to conference attendees during the scheduled\nsession. For more information, please visit asco.org (https://pr.report/kvr5).\n\nAbout Xenetic Biosciences\nXenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing\ninnovative immuno-oncology technologies addressing difficult to treat cancers.\nThe Company's proprietary DNase technology is designed to improve outcomes of\nexisting treatments, including immunotherapies, by targeting neutrophil\nextracellular traps (NETs), which are involved in cancer progression. Xenetic\nis currently focused on advancing its systemic DNase program into the clinic\nas an adjunctive therapy for pancreatic carcinoma and locally advanced or\nmetastatic solid tumors.\n\nFor more information, please visit the Company's website at www.xeneticbio.com\nand connect on X (https://pr.report/kvr7), LinkedIn (https://pr.report/kvr8),\nand Facebook (https://pr.report/kvr9).\n\nCONTACT:\nJTC Team, LLC\nJenene Thomas\n(908) 824-0775\nxbio@jtcir.com\n\nSOURCE: Xenetic Biosciences, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-abstract-acceptance-for-presentation-at-the-2026-a-1159779)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSC7x6Ma","title":"Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting","author":"ACCESSWIRE","ticker":"XBIO","created":"2026-04-22T13:00:02.957Z","tickers":["XBIO"],"exchange":"NASDAQ","article_body":"FRAMINGHAM, MA / ACCESS Newswire (https://www.accessnewswire.com/) / April 22,\n2026 / Xenetic Biosciences, Inc. (https://pr.report/kvr3) (NASDAQ:XBIO)\n(\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing\ninnovative immuno-oncology technologies addressing difficult to treat cancers,\ntoday announced that its abstract has been accepted for presentation at the\n2026 American Society of Clinical Oncology (ASCO) Annual Meeting\n(https://pr.report/kvr4), taking place May 29 - June 2, 2026, in Chicago, IL.\n(https://app.accessnewswire.com/imagelibrary/270296a6-00d1-405c-ad8e-010cf3e62669/1159779/xenetic-newlogo-031226.jpg)\nThe accepted abstract, titled \"Targeting cfDNA and NETs with DNase I to\naugment CAR T cell function and antitumor efficacy,\" highlights preclinical\nresearch supporting Xenetic's DNase-based therapeutic approach designed to\nenhance CAR T-cell activity and improve antitumor responses.\n\nPresentation Details:\n*\nSession Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster\nSession)\n*\nAbstract Title: Targeting cfDNA and NETs with DNase I to augment CAR T cell\nfunction and antitumor efficacy\n*\nPoster Board: 410\n*\nPresentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT\n*\nPresenter: Alexey V. Stepanov, PhD\n\nThe poster will be available to conference attendees during the scheduled\nsession. For more information, please visit asco.org (https://pr.report/kvr5).\n\nAbout Xenetic Biosciences\nXenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing\ninnovative immuno-oncology technologies addressing difficult to treat cancers.\nThe Company's proprietary DNase technology is designed to improve outcomes of\nexisting treatments, including immunotherapies, by targeting neutrophil\nextracellular traps (NETs), which are involved in cancer progression. Xenetic\nis currently focused on advancing its systemic DNase program into the clinic\nas an adjunctive therapy for pancreatic carcinoma and locally advanced or\nmetastatic solid tumors.\n\nFor more information, please visit the Company's website at www.xeneticbio.com\nand connect on X (https://pr.report/kvr7), LinkedIn (https://pr.report/kvr8),\nand Facebook (https://pr.report/kvr9).\n\nCONTACT:\nJTC Team, LLC\nJenene Thomas\n(908) 824-0775\nxbio@jtcir.com\n\nSOURCE: Xenetic Biosciences, Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-abstract-acceptance-for-presentation-at-the-2026-a-1159779)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-04-22T13:00:03.044152303Z","server_sent_at_ms":1776862803044},"received_at":"2026-04-22T13:00:03.095Z","source_url":"https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-abstract-acceptance-for-presentation-at-the-2026-a-1159779"},"analysis":{"id":"3451","press_release_id":"4840","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Xenetic Biosciences announced that an abstract highlighting preclinical research on its DNase-based therapeutic approach has been accepted for presentation at the 2026 ASCO Annual Meeting.\n\nThe abstract details how targeting cfDNA and NETs with DNase I can augment CAR T cell function and improve antitumor efficacy.\n\nThe poster presentation is scheduled for June 1, 2026, during the Hematologic Malignancies - Plasma Cell Dyscrasia session in Chicago.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":""},"namedEntities":{"people":[{"name":"Alexey V. Stepanov","role":"Presenter"}],"products":["DNase I","CAR T cell"],"companies":[{"name":"Xenetic Biosciences, Inc.","ticker":"XBIO"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of preclinical abstract acceptance for a poster presentation; no clinical data or financial metrics released."},"tickerRelevance":{"others":[],"primary":"XBIO"},"eventTypeSecondary":[]},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Xenetic Biosciences announced that an abstract highlighting preclinical research on its DNase-based therapeutic approach has been accepted for presentation at the 2026 ASCO Annual Meeting.\n\nThe abstract details how targeting cfDNA and NETs with DNase I can augment CAR T cell function and improve antitumor efficacy.\n\nThe poster presentation is scheduled for June 1, 2026, during the Hematologic Malignancies - Plasma Cell Dyscrasia session in Chicago.","key_figures":null,"named_entities":{"people":[{"name":"Alexey V. Stepanov","role":"Presenter"}],"products":["DNase I","CAR T cell"],"companies":[{"name":"Xenetic Biosciences, Inc.","ticker":"XBIO"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T17:18:00.330Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.210Z"}},"durationMs":49825,"modelName":"glm-4.7"}}